SCHEMBL6287035

SCHEMBL6287035

CC1CC(=O)Nc2ccc(C(=O)CCl)cc21

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
MAPT P10636 1/20 0.50
KDM4E B2RXH2 1/20 0.38
NEK2 P51955 4/20 0.38
SMYD3 Q9H7B4 3/20 0.38
CDK1 P06493 2/20 0.38
CCNB1 P14635 2/20 0.38
RAF1 P04049 1/20 0.37
BRD4 O60885 1/20 0.37
CREBBP Q92793 1/20 0.37
EPHX2 P34913 1/20 0.37
MAPK1 P28482 1/20 0.36
GSK3B P49841 1/20 0.36
TSHR P16473 1/20 0.35
CASP3 P42574 1/20 0.35
CASP2 P42575 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9366168 1.00 ALDH1A1 (0.50) ALDH1A1MAPTKDM4ENEK2SMYD3
SCHEMBL9367565 1.00 ALDH1A1 (0.50) ALDH1A1MAPTKDM4ENEK2SMYD3
SCHEMBL6219737 0.90 ALDH1A1 (0.40) ALDH1A1MAPTKDM4ESMYD3BRD4
SCHEMBL9376059 0.82 BRD4 (0.47) ALDH1A1KDM4ESMYD3BRD4CREBBP
SCHEMBL9366243 0.80 ALDH1A1 (0.38) ALDH1A1MAPTSMYD3MAPK1GSK3B
SCHEMBL7434105 0.79 PGR (0.48) ALDH1A1MAPTKDM4ENEK2CDK1
SCHEMBL6748219 0.78 ALDH1A1 (0.43) ALDH1A1MAPTKDM4ENEK2CDK1
SCHEMBL8480632 0.77 ALDH1A1 (0.46) ALDH1A1MAPTKDM4ENEK2SMYD3
SCHEMBL11333153 0.76 KMT2A (0.39) ALDH1A1SMYD3BRD4CREBBPMAPK1
SCHEMBL6447943 0.76 ALDH1A1 (0.41) ALDH1A1MAPTKDM4ENEK2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546143-A1 HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2005-06-29 EP disclosed
US-20040138230-A1 Heterocyclic substituted piperazines for the treatment of schizophrenia ANDREANA TONJA LYNN (US) 2004-07-15 US disclosed
WO-2004026864-A1 HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2004-04-01 WO disclosed
EP-0409435-B1 Heteroaryl piperazine antipsychotic agents PFIZER (US) 1994-10-26 EP disclosed
US-5350747-A Heteroaryl piperazine antipsychotic agents PFIZER INC (US) 1994-09-27 US disclosed
WO-1991000863-A1 HETEROARYL PIPERAZINE ANTIPSYCHOTIC AGENTS PFIZER INC. (US) 1991-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138230-A1 Heterocyclic substituted piperazines for the treatment of schizophrenia CNR1, DRD2, CNR2 ALDH1A1 460/4885MAPT 2926/4885KDM4E 1123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.